Overview of infused cellular products
| Patient # | Cohort | No of DC vaccines | Total no of injected DC per vaccine (x106) | No of infused TILs (billions) | Total no of IL-2 doses | %CD8 | %CD8 Mart-1+ | Clinical response* | OS† Months | PFS months |
| 126 | TIL | 0 | 0 | 8 | 14 | 22.7 | 6.94 | SD | 8‡ | 5 |
| 228 | TIL | 0 | 0 | 74 | 11 | 80.4 | 0.072 | PD | 129 | 2 |
| 232 | TIL | 0 | 0 | 99 | 17 | 95.4 | 64.7 | PD | 86 | 4 |
| 307 | TIL | 0 | 0 | 46 | 18 | 91.7 | 4.95 | PR | 49‡ | 11 |
| 351 | TIL | 0 | 0 | 32.6 | 15 | 18.7 | 0.16 | PD | 14‡ | 2 |
| 408 | TIL | 0 | 0 | 69 | 14 | 80.5 | 6.25 | SD | 83 | 4 |
| 411 | TIL | 0 | 0 | 14.3 | 11 | 38.5 | 1.31 | PD | 22‡ | 1 |
| 420 | TIL | 0 | 0 | 43.8 | 14 | 13.7 | 1.83 | SD | 15 | 3 |
| 448 | TIL | 0 | 0 | 27.3 | 12 | 35.8 | 0.13 | CR | 53‡ | 18 |
| 456 | TIL | 0 | 0 | 1.7 | 17 | 56.9 | – | PR | 11‡ | 2 |
| 120 | TIL+DC | 2 | 250 | 44.6 | 17 | 18 | 3.01 | SD | 17‡ | 6 |
| 151 | TIL+DC | 2 | 184 | 62 | 14 | 76.4 | 0.72 | SD | 102 | 5 |
| 172 | TIL+DC | 2 | 209 | 115 | 15 | 81.4 | 0.82 | CR | 137 | – |
| 177 | TIL+DC | 1§ | 478 | 130 | 3 | 97.2 | 0.28 | PD | 2‡ | 0 |
| 302 | TIL+DC | 2 | 201 | 104.5 | 10 | 95.1 | 96.6 | PR | 7‡ | 7 |
| 312 | TIL+DC | 2 | 328 | 107 | 12 | 66.3 | 1.63 | PD | 119 | 1 |
| 380 | TIL+DC | 2 | 250 | 16.3 | 13 | 4.68 | 17.8 | PR | 17‡ | 8 |
| 412 | TIL+DC | 2 | 98 | 55 | 12 | 72 | – | PR | 31‡ | 7 |
*Best overall response measured by irRC.
†As of September 2020.
‡Deceased.
§Patient died before second DC dose.
ACT, adoptive cell therapy; CR, complete response; DCs, dendritic cells; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression free survival; PR, partial response; SD, stable disease; TILs, tumor-infiltrating lymphocytes.